Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a synthetic pentasaccharide anticoagulant that acts as a selective inhibitor of factor Xa. It is used in the management of venous thromboembolism, unstable angina and acute myocardial infarction. It is given by subcutaneous injection once daily.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (elevated molecular weight and high percentage of plasma protein binding) make it highly unlikely that significant quantities will pass into breast milk.
Its null oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk (EMA 2007), except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.
Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding.(Lactmed, Hale, Bates 2018, Briggs 2015, Schaefer 2015)